Apretude® (cabotegravir intramuscular injection)

Apretude (cabotegravir IM) is covered only for FDA‑approved PrEP to reduce sexually acquired HIV‑1 in at‑risk adults and adolescents ≥35 kg and is not covered for treatment of established HIV infection. Coverage requires a negative HIV‑1 test within 7 days before each dose, absence of acute HIV symptoms, prescription as part of a comprehensive prevention strategy, dosing per label (600 mg IM at initiation one month apart then 600 mg every 2 months; if oral lead‑in used, injections on last day or within 3 days), prescriber is or consulted with an HIV specialist, documentation of weight/tests/counseling and injection records, and approvals are granted for up to 12 months.

"Apretude is indicated in at-risk adults and adolescents weighing at least 35 kg for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection."

Sign up to see full coverage criteria, indications, and limitations.